Capital World Investors Sells 1,595,585 Shares of Precision BioSciences, Inc. (NASDAQ:DTIL)

Capital World Investors reduced its holdings in shares of Precision BioSciences, Inc. (NASDAQ:DTILFree Report) by 23.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 5,119,458 shares of the company’s stock after selling 1,595,585 shares during the period. Capital World Investors owned about 4.20% of Precision BioSciences worth $1,869,000 at the end of the most recent reporting period.

Separately, Acadian Asset Management LLC grew its holdings in shares of Precision BioSciences by 8.3% during the 3rd quarter. Acadian Asset Management LLC now owns 3,148,243 shares of the company’s stock valued at $1,073,000 after purchasing an additional 242,425 shares during the last quarter. Institutional investors own 37.99% of the company’s stock.

Precision BioSciences Stock Down 2.7 %

NASDAQ:DTIL opened at $12.20 on Friday. The firm has a market capitalization of $84.55 million, a P/E ratio of -1.63 and a beta of 1.75. Precision BioSciences, Inc. has a 52 week low of $8.25 and a 52 week high of $23.96. The company has a fifty day moving average of $12.17 and a 200 day moving average of $12.08.

Precision BioSciences (NASDAQ:DTILGet Free Report) last posted its earnings results on Monday, May 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.10. Precision BioSciences had a negative net margin of 48.10% and a negative return on equity of 131.69%. The company had revenue of $17.58 million during the quarter, compared to analyst estimates of $9.35 million. As a group, analysts anticipate that Precision BioSciences, Inc. will post -2.99 EPS for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on DTIL. HC Wainwright reissued a “buy” rating and issued a $60.00 price target on shares of Precision BioSciences in a research note on Thursday, May 30th. Guggenheim started coverage on Precision BioSciences in a research note on Tuesday, April 30th. They issued a “buy” rating and a $19.00 target price for the company.

View Our Latest Research Report on Precision BioSciences

Precision BioSciences Company Profile

(Free Report)

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.

Featured Stories

Want to see what other hedge funds are holding DTIL? Visit to get the latest 13F filings and insider trades for Precision BioSciences, Inc. (NASDAQ:DTILFree Report).

Institutional Ownership by Quarter for Precision BioSciences (NASDAQ:DTIL)

Receive News & Ratings for Precision BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precision BioSciences and related companies with's FREE daily email newsletter.